Results 131 to 140 of about 14,556 (187)

Which surfactant is cost-effective in Neonatal Respiratory Distress Syndrome? [PDF]

Cost Eff Resour Alloc
Nikakhtar G, Karimi Majd Z, Ghasemi Z, Akhtari N, Yousefi N.   +4 more
europepmc   +1 more source

Evidence Synthesis via Indirect Treatment Comparisons in the European Framework of Joint Clinical Assessment. [PDF]

Epidemiologia (Basel)
Cuadra-Grande A, Arruñada M, García-Solís A, Rossignoli-Montero A, Casado MÁ.   +4 more
europepmc   +1 more source

Lost in Translation? A Scoping Review to Explore the Translation and Cultural Adaptation of Preference-Based Measures of Quality of Life. [PDF]

Appl Health Econ Health Policy
Cleland J, Lay K, Ratcliffe J, Khadka J.
europepmc   +1 more source

The Cost Utility of Rhythm Control Treatment Sequences in Patients with Atrial Fibrillation: Anti-arrhythmic Drugs Versus Catheter Ablation. [PDF]

Pharmacoeconomics
Huygens S, Versteegh M, Hemels M, Linz D, Rienstra M, Yap SC.   +5 more
europepmc   +1 more source

Changes in the Use of Montelukast for Asthma After a US Food and Drug Administration Boxed Warning.

JAMA Netw Open
Shanmugam H, Kesselheim AS, Liu ITT, Feldman WB, Rome BN.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pharmacoeconomics of voriconazole

Expert Opinion on Pharmacotherapy, 2010
The recent increase in the use of antineoplastic and immune suppressive agents and the use of broad-spectrum antibiotics, prosthetic interventions, organ transplants and more aggressive surgery have been related to a greater prevalence of invasive fungal infections (IFI).
Santiago Grau, CARLOS Rubio-Terres
exaly   +3 more sources

Pharmacoeconomics: the truth

Lancet, The, 1993
Peter Davey
exaly   +3 more sources